Top

Supportive Care in Cancer

Published in:

01-12-2021 | Anemia | Original Article

Risk prediction models based on hematological/body parameters for chemotherapy-induced adverse effects in Chinese colorectal cancer patients

Authors: Mingming Li, Jiani Chen, Yi Deng, Tao Yan, Haixia Gu, Yanjun Zhou, Houshan Yao, Hua Wei, Wansheng Chen

Published in: Supportive Care in Cancer | Issue 12/2021

Abstract

Purpose

To determine risk factors and develop novel prediction models for chemotherapy-induced adverse effects (CIAEs) in Chinese colorectal cancer (CRC) patients receiving capecitabine.

Methods

A total of 233 Chinese CRC patients receiving post-operative chemotherapy with capecitabine were randomly divided into a training set (70%) and a validation set (30%). CIAE-related hematological/body parameters were screened by univariate logistic regression. Based on a set of factors selected from LASSO (least absolute shrinkage and selection operator) logistic regression, stepwise multivariate logistic regression was applied to develop prediction models. Area under the receiver operating characteristic (ROC) curve and Hosmer–Lemeshow (HL) test were used to evaluate the discriminatory ability and the goodness of fit of each model.

Results

In total, 35 variables were identified to be associated with CIAEs in univariate analysis. Developed multivariable models had AUCs (area under curve) ranging from 0.625 to 0.888 and 0.428 to 0.760 in the training and validation set, respectively. The grade ≥ 1 anemia multivariable model achieved the best discriminatory ability with AUC of 0.760 (95%CI: 0.609–0.912) and good calibration with HL P value of 0.450. Then, a nomogram was constructed to predict grade ≥ 1 anemia, which included variables of age, pre-operative hemoglobin count, and pre-operative albumin count, with C-indexes of 0.775 and 0.806 in the training and validation set, respectively.

Conclusions

This study identified valuable hematological/body parameters related to CIAEs. A nomogram based on the multivariable model including three hematological/body predictors can accurately predict grade ≥ 1 anemia, facilitating clinicians to implement personalized medicine early for Chinese CRC patients receiving post-operative chemotherapy for better safety treatment.

Trial registration

This study was registered as a clinical trial at www.clinicaltrials.gov (NCT03030508).

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492CrossRef

Zhang Y, Chen Z, Li J (2017) The current status of treatment for colorectal cancer in China: a systematic review. Medicine (Baltimore) 96:e8242. https://doi.org/10.1097/MD.0000000000008242CrossRef

Chen Y, Zhang M, Qin H et al (2017) Correlation between oral chemotherapy adherence and illness perception in colorectal cancer patients: a longitudinal study. Chin J Nurs 52:8–13. https://doi.org/10.3761/j.issn.0254-1769.2017.01.001CrossRef

Ychou M, Rivoire M, Thezenas S et al (2013) A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial Ann Surg Oncol 20:4289–4297. https://doi.org/10.1245/s10434-013-3217-xCrossRefPubMed

Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN Guidelines insights: colon cancer, Version 2.2018. J Natl Compr Canc Netw 16:359–369. https://doi.org/10.6004/jnccn.2018.0021CrossRefPubMed

Hasegawa Y, Iwata H, Hatanaka M (2014) A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs. Gan To Kagaku Ryoho 41:383–385PubMed

Zheng QH, Wu XL, Che XL et al (2014) Chemotherapy combined with target drugs in the treatment of advanced colorectal cancer: a meta-analysis based on Chinese patients. Indian J Cancer 51(Suppl 3):e110-112. https://doi.org/10.4103/0019-509X.154100CrossRefPubMed

Hofheinz RD, Gencer D, Schulz H et al (2015) Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol 33:2444–2449. https://doi.org/10.1200/JCO.2014.60.4587CrossRefPubMed

Yap YS, Kwok LL, Syn N et al (2017) Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 3:1538–1545. https://doi.org/10.1001/jamaoncol.2017.1269CrossRefPubMedPubMedCentral

10.

Chan SL, Chan AWH, Mo F et al (2018) Association between serum folate level and toxicity of capecitabine during treatment for colorectal cancer. Oncologist 23:1436–1445. https://doi.org/10.1634/theoncologist.2017-0637CrossRefPubMedPubMedCentral

11.

García-González X, Cortejoso L, García MI et al (2015) Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget 6:6422–6430. https://doi.org/10.18632/oncotarget.3289CrossRefPubMedPubMedCentral

12.

Newman NB, Sidhu MK, Baby R et al (2016) Long-term bone marrow suppression during postoperative chemotherapy in rectal cancer patients after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 94:1052–1060. https://doi.org/10.1016/j.ijrobp.2015.12.374CrossRefPubMed

13.

Kawakami K, Nakamoto E, Yokokawa T et al (2015) Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence 9:561–567. https://doi.org/10.2147/PPA.S80327CrossRefPubMedPubMedCentral

14.

López-Pousa A, Rifà J, Casas de Tejerina A et al (2010) Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care (Engl) 19:648–655. https://doi.org/10.1111/j.1365-2354.2009.01121.xCrossRef

15.

Deng B, Sun W (2018) Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis. Phytother Res 32:1211–1228. https://doi.org/10.1002/ptr.6068CrossRefPubMed

16.

Deng Y, Yao H, Chen W et al (2020) Profiling of polar urine metabolite extracts from Chinese colorectal cancer patients to screen for potential diagnostic and adverse-effect biomarkers. J Cancer 11:6925–6938. https://doi.org/10.7150/jca.47631CrossRefPubMedPubMedCentral

17.

Ueland PM, Ulvik A, Rios-Avila L et al (2015) Direct and functional biomarkers of Vitamin B6 status. Annu Rev Nutr 35:33–70. https://doi.org/10.1146/annurev-nutr-071714-034330CrossRefPubMedPubMedCentral

18.

Zuo H, Ueland PM, Eussen SJPM et al (2015) Markers of vitamin B6 status and metabolism as predictors of incident cancer: the Hordaland Health Study. Int J Cancer 136:2932–2939. https://doi.org/10.1002/ijc.29345CrossRefPubMed

19.

Langius JAE, Zandbergen MC, Eerenstein SEJ et al (2013) Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. Clin Nutr 32:671–678. https://doi.org/10.1016/j.clnu.2013.06.012CrossRefPubMed

20.

Visser J, McLachlan MH, Maayan N, Garner P (2018) Community-based supplementary feeding for food insecure, vulnerable and malnourished populations - an overview of systematic reviews. Cochrane Database Syst Rev 11:CD010578. https://doi.org/10.1002/14651858.CD010578.pub2CrossRefPubMed

21.

Sim X, Poncz M, Gadue P, French DL (2016) Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets. Blood 127:1227–1233. https://doi.org/10.1182/blood-2015-08-607929CrossRefPubMedPubMedCentral

22.

Chen W, Li M, Yao H et al (2018) Application values of tumor markers and inflammatory markers in diagnosis of colorectal cancer and prediction of chemotherapy-related adverse effects. Tumor 38:1038–1047. https://doi.org/10.3781/j.issn.1000-7431.2018.11.564CrossRef

23.

Xu R, Li J, Yuan Y et al (2018) Preliminary study on prediction model of adverse reactions in patients with lymphatic tumors after chemotherapy with high dose methotrexat. Chinese Journal of Modern Applied Pharmacy 35:878–883. https://doi.org/10.13748/j.cnki.issn1007-7693.2018.06.020CrossRef

24.

Moreau M, Klastersky J, Schwarzbold A et al (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513–519. https://doi.org/10.1093/annonc/mdn655CrossRefPubMed

25.

Molassiotis A, Stamataki Z, Kontopantelis E (2013) Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 21:2759–2767. https://doi.org/10.1007/s00520-013-1843-2CrossRefPubMed

26.

Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177. https://doi.org/10.1007/s00520-009-0737-9CrossRefPubMed

27.

Razzaghdoust A, Mofid B, Moghadam M (2018) Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy. Support Care Cancer 26:3691–3699. https://doi.org/10.1007/s00520-018-4224-zCrossRefPubMed

28.

Seo SH, Kim S-E, Kang Y-K et al (2016) Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer 16:900. https://doi.org/10.1186/s12885-016-2934-5CrossRefPubMedPubMedCentral

29.

He Y, Jian Z, OuYang M et al (2004) Using mini-nutritional assessment to investigate the nutritional status of the aged hospitalized patients. Chin J Clin Nutr 2004:20–23

30.

Lei B, Zheng G (2015) Chemotherapy-induced myelosuppression of non-small cell lung cancer: clinical analysis of risk factors and development of a predictive model. Journal of Clinical Medical Literature 2: https://doi.org/10.16281/j.cnki.jocml.2015.36.01

31.

National Institutes of Health, National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) Version 4.0. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES

32.

Han SS, Azad TD, Suarez PA, Ratliff JK (2019) A machine learning approach for predictive models of adverse events following spine surgery. Spine J 19:1772–1781. https://doi.org/10.1016/j.spinee.2019.06.018CrossRefPubMed

33.

Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787–794. https://doi.org/10.1016/j.jaad.2014.03.019CrossRefPubMed

34.

Heo YS, Chang HM, Kim TW et al (2004) Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44:1166–1172. https://doi.org/10.1177/0091270004268321CrossRefPubMed

35.

Hofheinz R-D, Heinemann V, von Weikersthal LF et al (2012) Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 107:1678–1683. https://doi.org/10.1038/bjc.2012.434CrossRefPubMedPubMedCentral

36.

Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348–1353. https://doi.org/10.1093/annonc/mdr400CrossRefPubMed

37.

Forbes CA, Worthy G, Harker J et al (2014) Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review. Clin Ther 36:594–610. https://doi.org/10.1016/j.clinthera.2014.02.007CrossRefPubMed

38.

Javarappa KK, Tsallos D, Heckman CA (2018) A multiplexed screening assay to evaluate chemotherapy-induced myelosuppression using healthy peripheral blood and bone marrow. SLAS Discov 23:687–696. https://doi.org/10.1177/2472555218777968CrossRefPubMed

39.

Hénin E, You B, VanCutsem E et al (2009) A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 85:418–425. https://doi.org/10.1038/clpt.2008.220CrossRefPubMed

40.

Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15:1625–1633. https://doi.org/10.1080/14740338.2016.1238067CrossRefPubMed

41.

Sproston NR, Ashworth JJ (2018) Role of c-reactive protein at sites of inflammation and infection. Front Immunol 9:754. https://doi.org/10.3389/fimmu.2018.00754CrossRefPubMedPubMedCentral

42.

You J, Zhu G-Q, Xie L et al (2016) Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. Oncotarget 7:25516. https://doi.org/10.18632/oncotarget.8334CrossRefPubMedPubMedCentral

43.

Dimitriou N, Felekouras E, Karavokyros I et al (2018) Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer 18:1202. https://doi.org/10.1186/s12885-018-5042-xCrossRefPubMedPubMedCentral

44.

Sankaran VG, Weiss MJ (2015) Anemia: progress in molecular mechanisms and therapies. Nat Med 21:221–230. https://doi.org/10.1038/nm.3814CrossRefPubMedPubMedCentral

45.

Seita J, Weissman IL (2010) Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2:640–653. https://doi.org/10.1002/wsbm.86CrossRefPubMedPubMedCentral

46.

Mendelson A, Frenette PS (2014) Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 20:833–846. https://doi.org/10.1038/nm.3647CrossRefPubMedPubMedCentral

47.

Gordinier ME, Dizon DS, Fleming EL et al (2006) Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecol Oncol 103:72–74. https://doi.org/10.1016/j.ygyno.2006.01.031CrossRefPubMed

48.

Tanyi JL, Smith JA, Ramos L et al (2009) Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 114:219–224. https://doi.org/10.1016/j.ygyno.2009.04.007CrossRefPubMed

49.

Dranitsaris G, Molassiotis A, Clemons M et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267. https://doi.org/10.1093/annonc/mdx100CrossRefPubMedPubMedCentral

50.

Watanabe A, Yang CC, Cheung WY (2018) Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients. Med Oncol 35:125. https://doi.org/10.1007/s12032-018-1188-2CrossRefPubMed

51.

Egenvall M, Mörner M, Martling A, Gunnarsson U (2018) Prediction of outcome after curative surgery for colorectal cancer: preoperative haemoglobin, C-reactive protein and albumin. Colorectal Dis 20:26–34. https://doi.org/10.1111/codi.13807CrossRefPubMed

52.

Hao L, Ma J, Stampfer MJ et al (2003) Geographical, seasonal and gender differences in folate status among Chinese adults. J Nutr 133:3630–3635. https://doi.org/10.1093/jn/133.11.3630CrossRefPubMed

53.

Grimes CN, Fry MM (2015) Nonregenerative anemia: mechanisms of decreased or ineffective erythropoiesis. Vet Pathol 52:298–311. https://doi.org/10.1177/0300985814529315CrossRefPubMed

54.

Chao C, Xu L, Family L, Xu H (2016) A risk prediction model for severe chemotherapy-induced anemia in breast cancer patients. Blood 128:2399–2399. https://doi.org/10.1182/blood.V128.22.2399.2399CrossRef

55.

Ishizuka M, Fujimoto Y, Itoh Y et al (2011) Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin. Jpn J Clin Oncol 41:973–979. https://doi.org/10.1093/jjco/hyr076CrossRefPubMed

56.

Dranitsaris G, Clemons M, Verma S et al (2005) Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 6:856–863. https://doi.org/10.1016/S1470-2045(05)70394-6CrossRefPubMed

57.

Razzaghdoust A, Mofid B, Peyghambarlou P (2020) Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. Support Care Cancer 28:155–161. https://doi.org/10.1007/s00520-019-04780-7CrossRefPubMed

Title: Risk prediction models based on hematological/body parameters for chemotherapy-induced adverse effects in Chinese colorectal cancer patients
Authors: Mingming Li
Jiani Chen
Yi Deng
Tao Yan
Haixia Gu
Yanjun Zhou
Houshan Yao
Hua Wei
Wansheng Chen
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Anemia
Nausea
Vomiting
Colorectal Cancer
Colorectal Cancer
Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06337-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2021

The effectiveness of an oral health education and prevention program on the incidence and severity of oral mucositis in pediatric cancer patients: a non-randomized controlled study

‘Don’t forget the children’: a qualitative study when a parent is at end of life from cancer

A Japanese translation, cultural adaptation, and linguistic and content validity confirmation of the Scored Patient-Generated Subjective Global Assessment

The efficacy of music therapy to relieve pain, anxiety, and promote sleep quality, in patients with small cell lung cancer receiving platinum-based chemotherapy

Experiences with scans and scanxiety in people with advanced cancer: a qualitative study

Effect of home-based prehabilitation in an enhanced recovery after surgery program for patients undergoing colorectal cancer surgery during the COVID-19 pandemic

Keynote webinar | Spotlight on antibody–drug conjugates in cancer